AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Borthwick et al.						Docket No. PB60267USW	
Application No.	Filing Date	Examiner		Customer N	١٥.	Group Art Unit	Confirmation No.
10/561,414	12/19/05	J. Nolan	i	23347		1626	1165
Invention: PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS							
COMMISSIONER FOR PATENTS:							
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.							
CLAIMS AS AMENDED							
	CLAIMS REMAINING	HIGHEST#	NUMBI	ER EXTRA		RATE	ADDITIONAL
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS	PRESENT			FEE
TOTAL CLAIMS	9 -	20 =		0	x	\$50.00	\$0.00
INDEP. CLAIMS	2 -	3 =		0	х	\$210.00	\$0.00
Multiple Dependent Claims (check if applicable)							\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00							\$0.00
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 							
Robert (Steve) Thomas, Reg. No. 52,284 Attorney for Applicants							
GlaxoSmithKline Five Moore Drive, Research Triangle Telephone: (919) 48	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date)						
Signature of Person Mailing Co.							espondence

CC:

Typed or Printed Name of Person Mailing Correspondence